Format

Send to

Choose Destination
Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Author information

1
Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA. Electronic address: adam.boxer@ucsf.edu.
2
Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
3
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
4
Department of Neurology, University of California, San Diego, CA, USA.
5
Department of Neurology, University of Toronto, Toronto, ON, Canada.
6
Department of Neurology, Technical University of Munich, Munich, Germany; Department of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology SyNergy, Munich, Germany.

Abstract

Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases.

PMID:
28653647
PMCID:
PMC5802400
DOI:
10.1016/S1474-4422(17)30157-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center